Stroke Stem Cell Treatment


Stem Cell Treatment for StrokeStem Cell Treatment for a Stroke is an option

What is a Stroke?

Stroke and Stem Cell Therapy

A stroke (Cerebrovascular Accident or CVA), is the rapid loss of brain function due to the blood supply to the brain being disturbed. This can be from ischemia from the lack of blood flow or from a blockage known as Thrombosis, an Arterial Embolism, or a Haemorrhage where blood is leaking out or inside the brain.

The affected area of the brain is unable to function correctly and may result in an inability to move especially in one or more limbs on one side of the body. Stroke can also cause an inability to understand speech or speak or see properly. 

A stroke is a medical emergency that needs immediate medical attention. Stroke can cause permanent neurological damage and ongoing complications, and death. It is the a leading cause of adult disability in the around the world.

Risk factors for stroke include ederly people,  high blood pressure (hypertension), a previous stroke or from a transient ischemic attack (TIA).

Other related risk conditions include diabetes, high cholesterol, cigarette smoking and atrial fibrillation. High blood pressure is the most important modifiable risk factor of stroke.

A silent stroke is a stroke that does not have any outward symptoms, and the patient is typically unaware they have suffered a stroke. A silent stroke still causes damage to the brain, and places the person at risk for both transient ischemic attack and a major stroke occuring in the future.

People who have suffered a major stroke are at risk of having silent strokes as well.Stem Cell Treatment for Stroke


Stroke rehabilitation.

Lancet. 2011 May 14;377(9778):1693-702

Authors: Langhorne P, Bernhardt J, Kwakkel G

Stroke is a common, serious, and disabling global health-care problem, and rehabilitation is a major part of patient care. There is evidence to support rehabilitation in well coordinated multidisciplinary stroke units or through provision of early supported provision of discharge teams. Potentially beneficial treatment options for motor recovery of the arm include constraint-induced movement therapy and robotics.

Promising interventions that could be beneficial to improve aspects of gait include fitness training, high-intensity therapy, and repetitive-task training. Repetitive-task training might also improve transfer functions. Occupational therapy can improve activities of daily living; however, information about the clinical effect of various strategies of cognitive rehabilitation and strategies for aphasia and dysarthria is scarce. Several large trials of rehabilitation practice and of novel therapies (eg, stem-cell therapy, repetitive transcranial magnetic stimulation, virtual reality, robotic therapies, and drug augmentation) are underway to inform future practice.

PMID: 21571152 [PubMed - in process]


Stem Cell Treatment for Stroke NIH Streaming Database:

Related Articles Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord. Pharmacol Res. 2019 Mar 19;143:86-96 Authors: Kumar M, Kulshrestha R, Singh N, Jaggi AS Abstract Imatinib is a tyrosine kinase inhibitor and is used as a first line drug in the treatment of Philadelphia-chromosome-positive chronic myeloid leukaemia and gastrointestinal stromal tumors. Being tyrosine kinase inhibitor, imatinib modulates the activities of Abelson gene (c-Abl), Abelson related gene (ARG), platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinase 3 (FLT3), lymphocyte-specific protein (Lck), mitogen activated protein kinase (MAPK), amyloid precursor protein intracellular domain (AICD), α-synuclein and the stem-cell factor receptor (c-kit). Studies have shown the role of imatinib in modulating the pathophysiological state of a number of disorders affecting brain and spinal cord such as Alzheimer's disease, Parkinson's disease, stroke, multiple sclerosis and spinal cord injury. The present review discusses the role of imatinib in the above described disorders and the possible mechanisms involved in these diseases. PMID: 30902661 [PubMed - as supplied by publisher]
Related Articles SUMOylation promotes survival and integration of neural stem cell grafts in ischemic stroke. EBioMedicine. 2019 Mar 21;: Authors: Bernstock JD, Peruzzotti-Jametti L, Leonardi T, Vicario N, Ye D, Lee YJ, Maric D, Johnson KR, Mou Y, Van Den Bosch A, Winterbone M, Friedman GK, Franklin RJM, Hallenbeck JM, Pluchino S Abstract BACKGROUND: Neural stem cell (NSC)-based therapies hold great promise for treating diseases of the central nervous system (CNS). However, several fundamental problems still need to be overcome to fully exploit the clinical potential of NSC therapeutics. Chief among them is the limited survival of NSC grafts within hostile microenvironments. METHODS: Herein, we sought to engineer NSCs in an effort to increase graft survival within ischemic brain lesions via upregulation of global SUMOylation, a post-translational modification critically involved in mediating tolerance to ischemia/reperfusion. FINDINGS: NSCs overexpressing the SUMO E2-conjugase Ubc9 displayed resistance to oxygen-glucose-deprivation/restoration of oxygen/glucose (OGD/ROG) and enhanced neuronal differentiation in vitro, as well as increased survival and neuronal differentiation when transplanted in mice with transient middle cerebral artery occlusion in vivo. INTERPRETATION: Our work highlights a critical role for SUMOylation in NSC biology and identifies a biological pathway that can be targeted to increase the effectiveness of exogenous stem cell medicines in ischemic stroke. FUND: Intramural Research Program of the NINDS/NIH, the Italian Multiple Sclerosis Foundation (FISM), the Bascule Charitable Trust, NIH-IRTA-OxCam and Wellcome Trust Research Training Fellowships. PMID: 30905846 [PubMed - as supplied by publisher]

Quick Contact Form